Teck Long King, Shirley Siang Ning Tan, Lee Len Tiong, Irene Yee Yew Chieng, Wan Chung Law
{"title":"急性缺血性脑卒中患者抗血小板启动后血小板反应性的临床意义。","authors":"Teck Long King, Shirley Siang Ning Tan, Lee Len Tiong, Irene Yee Yew Chieng, Wan Chung Law","doi":"10.1186/s12883-025-04396-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High on-treatment platelet reactivity (HOTPR) may undermine the efficacy of antiplatelet therapy in acute stroke. This study aimed to assess platelet reactivity and HOTPR status during the acute phase of ischaemic stroke following antiplatelet initiation, and to determine their associations with stroke outcomes in a Malaysian cohort.</p><p><strong>Methods: </strong>This prospective, observational study enrolled patients with acute ischaemic stroke at Sarawak General Hospital. Platelet reactivity was measured at baseline and on Days 1 and 3 post-antiplatelet therapy using Multiplate<sup>®</sup> Analyser. HOTPR was defined by ASPItest (> 30 U) or ADPtest (> 46 U) values. The primary outcome was recurrent stroke at one year, while secondary outcomes included early neurological deterioration (END), poor functional outcome (mRS ≥ 2) at three months, and all-cause mortality at one year. Cox and logistic regression models adjusted for clinical covariates were used, with Firth's correction applied for rare events and model non-convergence.</p><p><strong>Results: </strong>A total of 198 participants were enrolled, with a mean age of 59.8 years; 66.7% were male. At one year, 9.1% experienced recurrent stroke, 9.6% had died, 9.2% experienced END during admission, and 21.6% had mRS ≥ 2 at three months. HOTPR rates decreased by Day 3 (aspirin: Day 1 20.0% to Day 3 6.6%; clopidogrel: 50.5-28.0%), with persistent HOTPR in 11.8% (aspirin) and 39.2% (clopidogrel). Some initially normal responders developed HOTPR by Day 3 (aspirin 5.4%, clopidogrel 16.3%). Platelet reactivity and HOTPR status on Days 1 and 3 were not significantly associated with recurrent stroke at one year or END. However, higher ADPtest values on Day 1 [OR 1.05 (95% CI 1.00, 1.09), p = 0.037], clopidogrel HOTPR on Days 1 and 3 [OR 20.99 (95% CI 1.53, 7089.91), p = 0.017; OR 16.58 (95% CI 1.57, 24326.82), p = 0.017], and persistent clopidogrel HOTPR on both days [OR 45.25 (95% CI 2.34, 21861.76), p = 0.007] were significantly associated with poor functional outcomes.</p><p><strong>Conclusion: </strong>Platelet reactivity and HOTPR status were not associated with recurrent stroke and END. However, higher ADPtest values and clopidogrel-related HOTPR were associated with poor functional outcomes. Further studies are needed to evaluate the clinical utility of platelet reactivity monitoring in acute stroke management.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"362"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382029/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical implications of platelet reactivity after antiplatelet initiation in patients with acute ischaemic stroke.\",\"authors\":\"Teck Long King, Shirley Siang Ning Tan, Lee Len Tiong, Irene Yee Yew Chieng, Wan Chung Law\",\"doi\":\"10.1186/s12883-025-04396-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>High on-treatment platelet reactivity (HOTPR) may undermine the efficacy of antiplatelet therapy in acute stroke. This study aimed to assess platelet reactivity and HOTPR status during the acute phase of ischaemic stroke following antiplatelet initiation, and to determine their associations with stroke outcomes in a Malaysian cohort.</p><p><strong>Methods: </strong>This prospective, observational study enrolled patients with acute ischaemic stroke at Sarawak General Hospital. Platelet reactivity was measured at baseline and on Days 1 and 3 post-antiplatelet therapy using Multiplate<sup>®</sup> Analyser. HOTPR was defined by ASPItest (> 30 U) or ADPtest (> 46 U) values. The primary outcome was recurrent stroke at one year, while secondary outcomes included early neurological deterioration (END), poor functional outcome (mRS ≥ 2) at three months, and all-cause mortality at one year. Cox and logistic regression models adjusted for clinical covariates were used, with Firth's correction applied for rare events and model non-convergence.</p><p><strong>Results: </strong>A total of 198 participants were enrolled, with a mean age of 59.8 years; 66.7% were male. At one year, 9.1% experienced recurrent stroke, 9.6% had died, 9.2% experienced END during admission, and 21.6% had mRS ≥ 2 at three months. HOTPR rates decreased by Day 3 (aspirin: Day 1 20.0% to Day 3 6.6%; clopidogrel: 50.5-28.0%), with persistent HOTPR in 11.8% (aspirin) and 39.2% (clopidogrel). Some initially normal responders developed HOTPR by Day 3 (aspirin 5.4%, clopidogrel 16.3%). Platelet reactivity and HOTPR status on Days 1 and 3 were not significantly associated with recurrent stroke at one year or END. However, higher ADPtest values on Day 1 [OR 1.05 (95% CI 1.00, 1.09), p = 0.037], clopidogrel HOTPR on Days 1 and 3 [OR 20.99 (95% CI 1.53, 7089.91), p = 0.017; OR 16.58 (95% CI 1.57, 24326.82), p = 0.017], and persistent clopidogrel HOTPR on both days [OR 45.25 (95% CI 2.34, 21861.76), p = 0.007] were significantly associated with poor functional outcomes.</p><p><strong>Conclusion: </strong>Platelet reactivity and HOTPR status were not associated with recurrent stroke and END. However, higher ADPtest values and clopidogrel-related HOTPR were associated with poor functional outcomes. Further studies are needed to evaluate the clinical utility of platelet reactivity monitoring in acute stroke management.</p>\",\"PeriodicalId\":9170,\"journal\":{\"name\":\"BMC Neurology\",\"volume\":\"25 1\",\"pages\":\"362\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382029/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12883-025-04396-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-025-04396-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:急性脑卒中患者治疗时血小板反应性高(HOTPR)可能会影响抗血小板治疗的疗效。本研究旨在评估抗血小板启动后缺血性卒中急性期血小板反应性和HOTPR状态,并确定它们与卒中结局的关系。方法:本前瞻性观察性研究纳入沙捞越总医院急性缺血性脑卒中患者。使用Multiplate®分析仪在基线和抗血小板治疗后第1天和第3天测量血小板反应性。HOTPR由ASPItest (> 30 U)或ADPtest (> 46 U)值定义。主要结局是一年后卒中复发,次要结局包括早期神经功能恶化(END)、3个月时功能不良(mRS≥2)和一年后全因死亡率。采用对临床协变量进行校正的Cox和logistic回归模型,对罕见事件和模型不收敛采用Firth校正。结果:共纳入198例受试者,平均年龄59.8岁;66.7%为男性。一年后,9.1%的患者卒中复发,9.6%的患者死亡,9.2%的患者入院时出现END, 21.6%的患者3个月时mRS≥2。HOTPR率在第3天下降(阿司匹林:第1天20.0%至第3天6.6%;氯吡格雷:50.5-28.0%),持续HOTPR为11.8%(阿司匹林)和39.2%(氯吡格雷)。一些最初正常反应者在第3天发生HOTPR(阿司匹林5.4%,氯吡格雷16.3%)。血小板反应性和HOTPR在第1天和第3天的状态与1年或终末期卒中复发无显著相关性。然而,ADPtest值在第1天较高[OR 1.05 (95% CI 1.00, 1.09), p = 0.037],氯吡格雷HOTPR在第1天和第3天较高[OR 20.99 (95% CI 1.53, 7089.91), p = 0.017;OR为16.58 (95% CI 1.57, 24326.82), p = 0.017],而两天持续使用氯吡格雷HOTPR [OR为45.25 (95% CI 2.34, 21861.76), p = 0.007]与功能不良结局显著相关。结论:血小板反应性和HOTPR状态与卒中复发和终末期无相关性。然而,较高的ADPtest值和氯吡格雷相关的HOTPR与较差的功能预后相关。血小板反应性监测在急性脑卒中治疗中的临床应用有待进一步研究。
Clinical implications of platelet reactivity after antiplatelet initiation in patients with acute ischaemic stroke.
Background: High on-treatment platelet reactivity (HOTPR) may undermine the efficacy of antiplatelet therapy in acute stroke. This study aimed to assess platelet reactivity and HOTPR status during the acute phase of ischaemic stroke following antiplatelet initiation, and to determine their associations with stroke outcomes in a Malaysian cohort.
Methods: This prospective, observational study enrolled patients with acute ischaemic stroke at Sarawak General Hospital. Platelet reactivity was measured at baseline and on Days 1 and 3 post-antiplatelet therapy using Multiplate® Analyser. HOTPR was defined by ASPItest (> 30 U) or ADPtest (> 46 U) values. The primary outcome was recurrent stroke at one year, while secondary outcomes included early neurological deterioration (END), poor functional outcome (mRS ≥ 2) at three months, and all-cause mortality at one year. Cox and logistic regression models adjusted for clinical covariates were used, with Firth's correction applied for rare events and model non-convergence.
Results: A total of 198 participants were enrolled, with a mean age of 59.8 years; 66.7% were male. At one year, 9.1% experienced recurrent stroke, 9.6% had died, 9.2% experienced END during admission, and 21.6% had mRS ≥ 2 at three months. HOTPR rates decreased by Day 3 (aspirin: Day 1 20.0% to Day 3 6.6%; clopidogrel: 50.5-28.0%), with persistent HOTPR in 11.8% (aspirin) and 39.2% (clopidogrel). Some initially normal responders developed HOTPR by Day 3 (aspirin 5.4%, clopidogrel 16.3%). Platelet reactivity and HOTPR status on Days 1 and 3 were not significantly associated with recurrent stroke at one year or END. However, higher ADPtest values on Day 1 [OR 1.05 (95% CI 1.00, 1.09), p = 0.037], clopidogrel HOTPR on Days 1 and 3 [OR 20.99 (95% CI 1.53, 7089.91), p = 0.017; OR 16.58 (95% CI 1.57, 24326.82), p = 0.017], and persistent clopidogrel HOTPR on both days [OR 45.25 (95% CI 2.34, 21861.76), p = 0.007] were significantly associated with poor functional outcomes.
Conclusion: Platelet reactivity and HOTPR status were not associated with recurrent stroke and END. However, higher ADPtest values and clopidogrel-related HOTPR were associated with poor functional outcomes. Further studies are needed to evaluate the clinical utility of platelet reactivity monitoring in acute stroke management.
期刊介绍:
BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.